Regulus Therapeutics Inc (NASDAQ:RGLS)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 1.60. At the close of trading, the stock’s price was $1.54, to imply a decrease of -3.75% or -$0.06 in intraday trading. The RGLS share’s 52-week high remains $3.79, putting it -146.1% down since that peak but still an impressive 29.87% since price per share fell to its 52-week low of $1.08. The company has a valuation of $100.87M, with an average of 0.27 million shares in intraday trading volume over the past 10 days and average of 338.49K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Regulus Therapeutics Inc (RGLS), translating to a mean rating of 1.33. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RGLS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.23.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
After registering a -3.75% downside in the last session, Regulus Therapeutics Inc (RGLS) has traded red over the past five days. The 5-day price performance for the stock is -0.65%, and 0.65% over 30 days. With these gigs, the year-to-date price performance is 20.31%. Short interest in Regulus Therapeutics Inc (NASDAQ:RGLS) saw shorts transact 1.4 million shares and set a 3.38 days time to cover.
Regulus Therapeutics Inc (RGLS) estimates and forecasts
Looking at statistics comparing Regulus Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Regulus Therapeutics Inc (RGLS) shares are -13.73% down over the last 6 months, with its year-to-date growth rate higher than industry average at 44.30% against 16.40%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 50.96% for the past 5-year period. While 2024 is set for a 46.10% return in earnings, projections for the next 5 years are at 39.60% annually.
RGLS Dividends
Regulus Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Regulus Therapeutics Inc insiders hold 1.69% of total outstanding shares, with institutional holders owning 88.26% of the shares at 89.77% float percentage. In total, 88.26% institutions holds shares in the company, led by FEDERATED HERMES, INC.. As of 2024-06-30, the company held over 12.85 million shares (or 19.9374% of shares), all amounting to roughly $22.94 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 3.97 million shares, or about 13.8063% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $7.08 million.
